GTS Securities LLC Makes New Investment in Genmab A/S (NASDAQ:GMAB)

GTS Securities LLC purchased a new position in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 74,356 shares of the company's stock, valued at approximately $1,552,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GMAB. China Universal Asset Management Co. Ltd. lifted its position in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after purchasing an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC grew its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares in the last quarter. Grandfield & Dodd LLC grew its holdings in Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after buying an additional 1,370 shares in the last quarter. Finally, Blue Trust Inc. increased its position in Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after acquiring an additional 1,442 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

NASDAQ:GMAB traded up $0.15 during trading hours on Thursday, hitting $21.34. 209,029 shares of the company's stock traded hands, compared to its average volume of 1,132,601. The stock's fifty day moving average price is $19.84 and its two-hundred day moving average price is $20.66. The firm has a market cap of $13.68 billion, a P/E ratio of 12.26, a P/E/G ratio of 2.65 and a beta of 1.04. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.